EX103 / ExcelMab - LARVOL DELTA

EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma (ASH 2023) - "Furthermore, EX103 demonstrates promising efficacy in heavily pretreated patients with R/R B-NHL, including some who have previously failed CAR-T treatment. The safety and efficacy of EX103 will be further evaluated in an ongoing clinical study."

Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD20 • IL6

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL) (ASH 2024) - P1/2 | "Conclusions : EX103 could induce high response rates in heavily pretreated R/R B-NHL patients, including impressive results for those who failed prior CD19 targeting therapies. It also has a favorable safety profile with low rates of severe CRS and without ICANS."

Clinical • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=415 | Recruiting | Sponsor: Guangzhou Excelmab Inc. | Trial primary completion date: Oct 2024 ➔ Oct 2025 | Trial completion date: Apr 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. (ASCO 2024) - "EX103 can induce deep and durable responses in heavily pretreated patients with R/R B-NHL, such as those patients who failed CAR-T treatment (3 cases), CD19xCD3 bispecific antibody treatment (2 cases) and ASCT (4 cases)."

Clinical • P1/2 data • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=415 | Recruiting | Sponsor: Guangzhou Excelmab Inc. | Phase classification: P1 ➔ P1/2 | N=138 ➔ 415

Enrollment change • Phase classification • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma (ESMO 2023) - "The preliminary Disease Control Rate (DCR) is 84.6% (11/13). Conclusions The preliminary data show favorable safety and remarkable antitumor activity, even at low doses, in heavily pretreated patients with R/R B-NHL, including those who failed prior CAR-T therapy."

Clinical • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL6

EX103 Bispecific Antibody Shows Safety and Early Efficacy in R/R B-cell NHL (Targeted Oncology) - P1 | N=138 | NCT06021678 | Sponsor: Guangzhou Excelmab Inc. | "Findings were presented at the 2023 ESMO Congress. In the dose-escalation portion of the study, results showed that evaluable patients treated with EX103 (n = 13) did not experience any dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD) had not been reached....Regarding efficacy, patients with relapsed/refractory diffuse large B-cell lymphoma treated with at least 6 mg of EX103 who were evaluable for response (n = 4) experienced an overall response rate (ORR) of 75.0%. All 3 responders achieved a complete response (CR), and the fourth patient had stable disease. In evaluable patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma (MZL) treated with at least 6 mg of EX103 (n = 4), the ORR was 100%, with all patients achieving a partial response (PR). One evaluable patient with mantle cell lymphoma (MCL) who received 3 mg of EX103 experienced a CR."

P1 data • Follicular Lymphoma • Marginal Zone Lymphoma

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=138 | Recruiting | Sponsor: Guangzhou Excelmab Inc.

New P1 trial • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology